Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Novo Nordisk's Victoza (liraglutide)

Victoza data shows promise for early setting

September 13, 2011 Research and Development, Sales and Marketing Novo Nordisk, Victoza

New data for Novo Nordisk’s Victoza could help the drug’s chances of being used in an earlier setting for type …
News

Aurobindo forms Russian joint venture with Diod

September 13, 2011 Manufacturing and Production, Sales and Marketing Aurobindo, Diod, pharma manufacturing news

Indian drugmaker Aurobindo has formed a joint venture with Russia’s OJSC Diod in order to tap into the local market …
News
research_partnership_richard_head

Richard Head joins the Research Partnership

September 12, 2011 Sales and Marketing appointment, sales and marketing

Market research company the Research Partnership has appointed Richard Head as a director. He will be based at the company’s …
Appointment

FDA recommends Xarelto for new approval

September 12, 2011 Sales and Marketing Xarelto, atrial fibrillation, stroke

FDA advisors have recommended Bayer and Johnson & Johnson’s Xarelto be approved in the US for the prevention of stroke …
News

GSK scales back breast cancer trial

September 12, 2011 Research and Development, Sales and Marketing GSK, Tyverb

GSK has halted one of the four phase III studies that make up the ALTTO programme for its cancer drug …
News

Takeda moves potential first-in-class diabetes drug into phase III

September 12, 2011 Research and Development, Sales and Marketing TAK-875, Takeda, diabetes

Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
News
Blog footer

Digital Pharma: Twitter slip-up shouldn’t silence pharma

September 9, 2011 Medical Communications, Sales and Marketing Bayer, Code of Practice, Digital Pharma blog, PMCPA, Twitter

Bayer UK was recently ruled to have breached the ABPI Code of Practice by promoting prescription-only medicines to the general …
News

EMA grants first paediatric use marketing authorisation

September 9, 2011 Sales and Marketing Buccolam, PUMA, Viropharma, paediatric trials, seizures

The first children’s medicine to hold a new paediatric use marketing authorisation (PUMA), making it available for children only, has …
News
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011 Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
News
Novartis

Everolimus approved to treat rare tumour disease

September 8, 2011 Sales and Marketing Novartis, SEGA, Votubia, everolimus

Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
News

New ABPI chief executive to focus on industry reputation

September 8, 2011 Research and Development, Sales and Marketing ABPI, industry relations

The new chief executive of the ABPI used his first public speech to focus on the reputation of the pharma …
News

Sanofi banks on personalised medicine for growth

September 8, 2011 Sales and Marketing Genzyme, Sanofi

Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …
News
Enbrel

Forecasting future launch success

September 8, 2011 Sales and Marketing Champix, Enbrel, forecast planning, forecasting

Pharmaceutical companies are moving into new and sometimes very different (often specialised) therapy areas, because of global market conditions and …
Feature

NICE recommends Takeda’s cancer drug Mepact

September 7, 2011 Sales and Marketing Mepact, NICE, Takeda

NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
News

Sanofi’s Multaq in the dock

September 7, 2011 Sales and Marketing Multaq, Sanofi

The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026